Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion~* Ambulatory, male or female patients aged ≥25 - ≤65 years~* Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4~* Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13~Key Exclusion Criteria:~* Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years.~* Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer~* Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy~* Inability to undergo brain MRI~* Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- WVE-120101 (Dose A) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose B) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose C) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose D) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose E) or placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).